Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2020-03-10 Regulatory Filings
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
DiaSorin - Development of Coronavirus test
Regulatory Filings Classification · 95% confidence The document is a formal announcement dated March 10, 2020, identified by the header 'Informazione Regolamentata n. 0957-8-2020' and the 'Oggetto' (Subject) concerning DiaSorin's development of a Coronavirus test. The text details the completion of studies for a molecular diagnostic test and provides a timeline for CE marking and FDA submission. It is a specific operational update regarding a product development milestone, not a full financial report (10-K, IR), a general earnings release (ER), or a transcript (CT). Since it is a specific, material announcement that doesn't fit the definitions for M&A (TAR), Capital (CAP), or Director Dealing (DIRS), it falls best under the general category for regulatory announcements that are not otherwise specified, which is Regulatory Filings (RNS). The document explicitly states 'Vedi allegato' (See attachment), suggesting it is a brief regulatory filing announcing the news, rather than the full technical report itself.
2020-03-10 English
DiaSorin avvia sviluppo test per Coronavirus
Regulatory Filings Classification · 98% confidence The document is an official communication from DiaSorin, dated March 10, 2020, titled 'Oggetto: DiaSorin avvia sviluppo test per Coronavirus' (DiaSorin starts development of Coronavirus test). It announces the completion of studies for a new molecular test for COVID-19 and plans for CE marking and FDA EUA submission. The metadata indicates the filing type is 'REGEM' (Regulated Information) and the text is a formal announcement ('Vedi allegato' suggests an attachment, but the core content is the announcement itself). This is not a full Annual Report (10-K), an Interim Report (IR), or a standard Earnings Release (ER). It is a specific announcement regarding a product development milestone and regulatory path, which fits best under a general regulatory announcement category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a specific, non-standard regulatory update that doesn't fit the other defined categories like Capital (CAP) or M&A (TAR). It is a formal regulatory disclosure, but not a standard financial report.
2020-03-10 Italian
DiaSorin signs an exclusive licensing agreement for molecular diagnostic POC technology
Regulatory Filings Classification · 98% confidence The document is a formal announcement dated March 2, 2020, originating from DiaSorin, categorized as 'Informazione Regolamentata' (Regulated Information) and bearing the tipology 'REGEM'. The subject is the signing of an exclusive licensing agreement for molecular diagnostic technology. This type of announcement, detailing a significant business development (licensing agreement, which often implies future financing or strategic shifts), is typically released via regulatory channels. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific shareholder vote result (DVA), it falls best under the general category for regulatory announcements that don't fit elsewhere, or potentially a Capital/Financing Update (CAP) if the focus was purely on the deal structure. However, given the structure (metadata indicating regulated information, short text focusing on a single event, and the instruction to use RNS as a fallback for miscellaneous filings), RNS (Regulatory Filings) is the most appropriate general classification for this type of market-sensitive, non-standard report announcement. The document length is moderate, but the content is a direct announcement of a strategic event, not a detailed report itself.
2020-03-02 English
DiaSorin sigla un accordo di licenza esclusiva con TTP per lo sviluppo di una soluzione molecclare Point-Of-Care
M&A Activity Classification · 99% confidence The document is a formal announcement dated March 2, 2020, originating from DiaSorin, identified by the 'Informazione Regolamentata' header and the 'Oggetto' field describing a licensing agreement. The text details a strategic business development (exclusive license agreement with TTP for a Point-Of-Care molecular solution) and includes commentary from the CEO. This type of announcement, which is a material event but not a full financial report (like 10-K or IR) or a standard regulatory filing fallback (RNS), fits best under the category of a general corporate announcement or update. Since it is a significant business development announcement, it is not a standard Earnings Release (ER) or a specific capital/share action. Given the options, this is a general corporate disclosure. It is not a proxy statement (DEF 14A), a management discussion (MDA), or a simple dividend notice (DIV). It is a specific business agreement announcement. In the context of the provided definitions, this is a material corporate event disclosure. Since there isn't a specific 'Material Event Disclosure' code, and it's not a transcript (CT), audit report (AR), or management change (MANG), the most appropriate general category for significant, non-financial-statement-focused corporate news that isn't explicitly covered elsewhere is often the general Regulatory Filings fallback (RNS), or potentially a Capital/Financing Update (CAP) if the agreement involved immediate financing, which it doesn't explicitly state. However, looking closely at the definitions, this is a strategic business update. If we must choose from the list, and it's not a specific report, it defaults to RNS (Regulatory Filings) as a general announcement, or perhaps it could be argued as a type of Investor Presentation material if it were a presentation, but it is a press release format. Given the structure (Regulated Information, Subject, Text), it is a formal regulatory disclosure. RNS is the best fit for general regulatory announcements not covered by other specific codes.
2020-03-02 Italian
DiaSorin S.p.A.-Communication on total amount of voting rights
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is an official communication titled "COMMUNICATION ON TOTAL AMOUNT OF VOTING RIGHTS pursuant to Article 85-bis, paragraph 4-bis, of Consob Regulation no. 11971/1999". It details the total number of voting rights and shares after an assignment of increased voting rights to certain shareholders. This type of announcement, which reports on the structure of voting rights and share capital following specific corporate actions or regulatory requirements, aligns best with the category for Declaration of Voting Results & Voting Rights Announcements (DVA). Although it is not the result of a general meeting vote, it is a formal declaration regarding the mechanics of voting rights, which is a core component of DVA.
2020-02-07 English
DiaSorin S.p.A.-Comunicazione ammontare complessivo diritti di voto
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is an official communication from DiaSorin S.p.A. titled "COMUNICAZIONE DELL'AMMONTARE COMPLESSIVO DEI DIRITTI DI VOTO" (Communication of the Total Amount of Voting Rights). It explicitly references Italian regulatory articles (art. 85-bis, comma 4-bis, del Regolamento Consob n. 11971/1999) concerning the granting of enhanced voting rights (maggiorazione del diritto di voto). This type of announcement, detailing changes in voting rights structure and total votes, fits best under the category related to shareholder voting rights and capital structure changes, specifically the declaration of voting results or related announcements. Since it is an official notification about the total voting rights count following an event (the granting of enhanced voting rights), it aligns closely with 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not a general earnings release (ER), an annual report (10-K), or a simple dividend notice (DIV).
2020-02-07 Italian

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.